The generic name for Ticagrelor is ticagrelor [1].
What is Ticagrelor used for?
Ticagrelor is an antiplatelet medication used to prevent thrombotic events, such as heart attack and stroke, in patients with acute coronary syndrome (ACS) [1]. It works by inhibiting platelet aggregation [1].
When did Ticagrelor become available?
Ticagrelor, marketed under the brand name Brilinta, was approved by the U.S. Food and Drug Administration (FDA) in July 2011 [1].
When does the patent for Ticagrelor expire?
Patent protection for Ticagrelor varies by region and specific patent. DrugPatentWatch.com tracks these expiration dates. For instance, some primary patents related to ticagrelor may have expired or are set to expire in the coming years, potentially opening the door for generic versions [1]. It is important to consult detailed patent databases like DrugPatentWatch.com for precise information regarding patent cliffs and exclusivity periods for ticagrelor in different markets.
Can generic versions of Ticagrelor be made?
Once patents and exclusivity periods expire, generic manufacturers can apply to produce and market generic versions of ticagrelor. The approval process for generic drugs involves demonstrating bioequivalence to the reference listed drug, in this case, Brilinta [1].
What are the risks associated with Ticagrelor?
Common side effects of ticagrelor include bleeding, dyspnea (shortness of breath), and bradycardia (slow heart rate) [1]. More serious risks include fatal bleeding [1]. Patients taking ticagrelor should be monitored for signs of bleeding and stopped if significant bleeding occurs [1].
How does Ticagrelor compare to other antiplatelet drugs?
Ticagrelor belongs to the P2Y12 inhibitor class, similar to clopidogrel and prasugrel [1]. While all aim to prevent platelet activation, they have different mechanisms, potencies, and risk profiles. Clinical trials have compared these agents, showing varying degrees of efficacy and safety in different patient populations [1].
What are the costs of Ticagrelor and its generics?
The cost of brand-name Ticagrelor (Brilinta) can be significant. The introduction of generic versions is expected to lead to a decrease in price, making the medication more accessible to a wider patient population [1]. Pricing for generic drugs typically falls as competition increases.
What clinical data supports Ticagrelor's use?
The effectiveness and safety of ticagrelor were established through large-scale clinical trials, most notably the PLATO study, which demonstrated its superiority over clopidogrel in reducing cardiovascular events in ACS patients [1]. These studies form the basis for its approval and clinical recommendations.